Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Mast Therapuetics Anticipates Top-Line Data from Phase 3 EPIC Study in Q2 of 2016

Source Link:: http://www.masttherapeutics.com/investors/news/?releaseid=2141456

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

MSTX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Mast Therapeutics recently completed enrollment of patients in its "phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study." The Company expects to report top-line results in the second quarter of 2016.

http://www.mastthera...

Clinical Data Update on 9.20.16: The study did not meet its primary efficacy endpoint of demonstrating a statistically significant reduction in the mean duration of VOC (82 hours in the vepoloxamer group compared to 78 hours in the placebo group in the intent-to-treat population (p=0.09)). There were no statistically significant differences between treatment groups in the intent-to-treat population across the two secondary efficacy endpoints, rate of re-hospitalization for VOC and the occurrence of acute chest syndrome. Consistent with previously conducted studies, vepoloxamer was generally well tolerated with no statistically significant differences in treatment-related serious adverse events in the vepoloxamer group compared to the placebo group. No deaths occurred on the study.

http://masttherapeut...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Sep 20, 2016

Occurred Source:

http://masttherapeutics.com/investors/news/?releaseid=2204897

Related Projects

Investigating the meaning of the recently announced delay in the database lock for Vepoloxamer's Phase 3 EPIC study MSTX Executed On: Jul 08, 2016 at 11:00 AM EDT
Analyzing the Previously Released Data on Mast Therapeutics' (MSTX) Vepoloxamer in Sickle Cell Disease and What It Can Tell Us About The Drug's Chance For Success In The Phase 3 EPIC Trial (Interview 1 of 3) MSTX, PFE, BLUE Executed On: May 03, 2016 at 10:30 AM EDT

Related Keywords Phase 3 Data, Vepoloxamer, Epic Trial, Sickle Cell Disease, Air001